Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise based in Melbourne, Australia, filed this Form 6-K for the month of September 2026. The report was signed by Chairman Julian Babarczy on September 16, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on regulatory filings rather than financial performance data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary activity reported is the submission of an application for the quotation of securities (ATH).
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. It serves primarily to incorporate an application for quotation of securities into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the status of the application for quotation of securities (ATH) referenced in Exhibit 99.1.
- Confirm the current development stage status of the company's therapeutic pipeline.
- Review the referenced Registration Statements (S-8 and F-3) for details on outstanding securities and capital structure.
- Check for subsequent filings that may contain the financial data absent from this specific Form 6-K.